Konala VM, Madhira BR, Ashraf S, et al. - This review was performed to explore if immunotherapy has any significance as a treatment choice for patients with extensive-stage small cell lung cancer (SCLC), focusing on its side effects as well as its limitations. For extensive-stage SCLC, platinum doublet chemotherapy with cisplatin or carboplatin combined with etoposide is the standard of care. Topotecan is the only FDA-approved second line therapy. Recently, approval has been granted to immunotherapy as a first-line agent in metastatic SCLC combined with chemotherapy. It has also received approval as a third-line option in metastatic SCLC following the failure of two chemotherapy regimens. For treating SCLC, the FDA has approved two PD-1 inhibitors (pembrolizumab and nivolumab) and two PD-L1 inhibitors (atezolizumab and durvalumab).